The week in pharma: action, reaction and insight – week to January 14, 2022
By Barbara Obstoj-Cardwell. Editor
Among last week’s notable announcements, US pharma giant Pfizer said it has entered into a gene base editing collaboration with Beam Therapeutics, which involves an upfront $300 million and up to $1.35 billion in milestones. Germany’s Bayer moved further into cell and gene therapies, announcing a $1 billion deal with Mammoth Biosciences. US biotech Biogen and Japanese partner Eisai took a hit last Tuesday, when the US federal insurer, Medicare, announced restrictions on the availability of their controversially approved Alzheimer’s treatment Aduhelm. Also, US drugmaker Vertex Pharmaceuticals gained an additional approval for its cystic fibrosis drug Kaftrio from the European Commission.
Beam collaboration with Pfizer to advance three based editing candidates
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze